Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
7,341 total articles
Adaptive Biotechnologies Corp's President and COO sold 57,180 shares between March 24 and March 26, 2026 under a pre-arranged 10b5-1 plan, generating about $802,235. She simultaneously exercised options to acquire 44,166 shares at $7.27 apiece for $321,086. The company recently reported stronger-than-expected fourth-quarter 2025 results and receive…
Rubrik Chief Financial Officer Choudary Kiran Kumar sold 122,613 Class A shares on March 24, 2026, generating $5.91 million, and converted 212,188 Class B shares to Class A the same day. The transaction occurred while the stock traded near a 52-week low. Separately, Rubrik reported quarterly results and guidance that topped FactSet consensus and in…
Rubrik Chief Technology Officer Arvind Nithrakashyap sold 28,967 shares of Class A common stock on March 24, 2026, for $48.1957 per share, netting $1,396,084. The same day he converted 40,625 Restricted Stock Units into shares at no cost. The stock is trading close to its 52-week low, while the company has reported quarterly results and forward gui…
David Raben, chief medical officer of Bicara Therapeutics Inc (NASDAQ: BCAX), sold 5,500 shares of the company's common stock on March 25, 2026, for about $104,229 while simultaneously exercising options to acquire an equal number of shares at a substantially lower strike. The transactions occurred just days ahead of Bicara's March 30 earnings repo…
DXP Enterprises director Timothy P. Halter sold 5,000 shares of the company’s common stock on March 26, 2026, at $139.57 per share, yielding $697,850. The transaction occurred while the stock traded near $137.06 after a roughly 60% gain over the prior year. The company reported mixed fourth-quarter fiscal 2025 results, missing EPS expectations but …
Magnetar Financial LLC, a 10% stakeholder in Wheeler Real Estate Investment Trust, sold 8,840 shares of WHLR common stock on March 26, 2026, at a weighted average price of $1.0964 for a total of $9,692. The transaction follows a March 24 acquisition of 172,075 shares at $0.01 and the disposition of a matching number of warrants. The sale and owners…
Definium Therapeutics Chief Legal Officer Mark Sullivan sold 10,702 common shares on March 25, 2026, under a Rule 10b5-1 plan to satisfy withholding tax obligations tied to vested restricted stock units. The transaction generated $197,665 at a weighted average price of $18.47 per share. Definium's recent fourth-quarter 2025 results showed heavy inv…
Definium Therapeutics Chief Executive Officer Robert Barrow sold 24,431 shares on March 25, 2026, for about $451,240 at weighted average prices between $18.36 and $18.80. The transaction, made under a Rule 10b5-1 plan adopted in 2022, was executed to meet withholding tax obligations related to vested restricted stock units. The stock is trading nea…
Definium Therapeutics, Inc. (NASDAQ:DFTX) Chief Medical Officer Daniel Karlin sold 8,018 shares on March 25, 2026, under a Rule 10b5-1 sell-to-cover election to satisfy withholding tax obligations. The transaction totaled $148,092 at a weighted average price of $18.47. Separately, the company reported fourth-quarter 2025 results showing a meaningfu…
Director Kamal Seyed Ghaffarian and related entities sold 283,818 Class A shares of Intuitive Machines (NASDAQ: LUNR) on March 24, 2026, for roughly $5.3 million under a Rule 10b5-1 plan. The trades, executed across several price points, coincided with a stock that has climbed 119% over the past year. The company also disclosed a major NASA payload…
Paula Soteropoulos, a member of Dianthus Therapeutics' board, sold 27,594 shares on March 24, 2026, for $78.05 each, generating $2.15 million in proceeds. On the same day she exercised options to acquire the same number of shares at $8.44 per share, costing $232,893. The company recently completed a sizable public offering that raised approximately…
Russell Low, President and CEO of Axcelis Technologies Inc (NASDAQ: ACLS), sold 1,244 shares on March 24, 2026, under a Rule 10b5-1 plan established in December 2025. The transaction totaled $111,960 at $90.00 per share. Axcelis reported stronger-than-expected fourth-quarter results but issued first-quarter guidance below analyst expectations. Conc…
Reliance Global Group Chairman and CEO Ezra Beyman purchased 300,000 shares of the company's common stock on March 26, 2026, paying $0.1699 per share for a total of $50,970. The transaction raises his direct stake to 959,299.997 shares. The company recently reported fourth-quarter 2025 results highlighting strategic shifts and technology investment…
Global Partners LP Chief Operating Officer Mark Romaine sold 2,065 common units on March 25, 2026, for total proceeds of $92,512. The units traded at a weighted average price of $44.80, within a range of $44.56 to $45.16. After the sale, Romaine directly holds 139,109 common units. The partnership, with a market capitalization of $1.53 billion and …
A 10% owner of Clene Inc. (NASDAQ: CLNN) sold 17,909 common shares across three transactions between March 24 and March 26, 2026, realizing $99,505. The stock has fallen 8.2% over the past week and was trading at $5.39 at the time of reporting. Separately, Clene announced progress on its ALS candidate CNM-Au8, including a planned in-person Type C m…
Asana, Inc. General Counsel and Corporate Secretary Katie Marie Colendich sold a total of 6,515 Class A shares on March 24 and 25, 2026, executing two tranches under a Rule 10b5-1 trading plan adopted June 27, 2025. The transactions totaled $41,781 and follow recent mixed quarterly results and downward adjustments to analyst price targets. Asana's …
Charles E. Martin, vice president and controller of Battalion Oil CORP (NASDAQ:BATL), sold 7,623 common shares on March 25, 2026, for $5.25 per share, a transaction totaling $40,020. The company has been active on several fronts recently, completing an acquisition in Ward County, Texas, closing a major asset sale, arranging new midstream capacity, …
Stephen C. Brinkley, President, Operations at Ross Stores, sold 4,154 shares on March 24, 2026, realizing $884,428. The transaction occurred as the stock traded near its 52-week high following a 69% year-over-year gain. Separate company results for fiscal fourth quarter 2025 beat expectations on both earnings and revenue, while several analysts rai…
Howard Hughes Holdings Inc.'s Chief Operating Officer, Andrew D. Davis, reported a sale of 1,636 shares on March 25, 2026, for $104,491, leaving him with 31,530 shares. Separately, the company’s fourth-quarter 2025 results showed a revenue beat of $624.4 million versus $596.8 million expected, but an earnings per share of $0.10 fell well below the …
A major shareholder of Gold.com, Inc. sold roughly $665,100 of stock on March 25, 2026. The transfer occurred at $45.00 per share and was followed by a decline in the stock price. Separately, Gold.com announced a $150 million private placement with TPM, S.A. de C.V., nominated a TPM representative to its board and received an analyst price-target l…
Verisign (NASDAQ:VRSN) Executive Vice President, General Counsel, and Secretary Thomas C. Indelicarto sold 498 shares on March 25, 2026 for $124,500, according to a Form 4 filing. The transaction comes as the company reported mixed fourth-quarter 2025 results - a revenue beat alongside an EPS shortfall - and while the stock has risen modestly over …
Ralph Smalling, Genelux Corp's Head of Regulatory, disposed of 585 shares across two transactions on March 24 and 25, 2026, to satisfy estimated tax obligations tied to vested restricted stock units. The company has simultaneously priced a public offering intended to raise about $20 million and reported encouraging trial data that underpins analyst…
Genelux Corporation reported an insider sale by Yu Yong, SVP of Clinical Development, who sold 906 shares on March 24, 2026, to satisfy estimated taxes tied to restricted stock units. The transaction occurred as the company moves forward with a priced public offering intended to raise roughly $20 million and after appointing a new chief medical off…
Genelux President and CEO Thomas Zindrick sold 3,582 shares on March 24, 2026 at $2.42 per share to cover taxes tied to restricted stock unit vesting. The transaction left him with 534,849 shares. The stock later traded at $2.63 but remains well below its 52-week high as the company faces negative free cash flow and recently priced a public offerin…
Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 10,115 shares of common stock on March 25, 2026, generating roughly $303,354. The trades were executed under a Rule 10b5-1 plan at prices between $29.90 and $30.18. The company recently reported fiscal 2025 results and released Phase IIa data for RAP-219 in focal seizures, …
